Introduction
Autism has been linked to gastrointestinal (GI) disturbances (White
2003). It is, however, questionable whether GI anomalies in children with autism are specific (Erickson et al.,
2005). An increase of chronic diarrhea, constipation, abdominal bloating and food regurgitation has been found in some studies, but could not be confirmed in more recent studies (reviewed by Erickson et al.
2005). Increased GI permeability, as established through the differential sugar absorption test (SAT), was demonstrated in 9/21 (43%) (D’Eufemia et al.,
1996) and 19/26 (76%) (Horvath & Perman,
2002) of patients diagnosed with autism. The SAT measures the integrity of the intestine by the ingestion of two indigestible saccharides that after GI uptake become fully excreted in urine. One of these (usually lactulose) passes the intestinal wall through paracellular transport (‘leakage’), while the other (usually mannitol) passes by paracellular and transcellular transport. The urinary lactulose/mannitol ratio is used as a measure of intestinal integrity and permeability (van Elburg et al.,
1995). In addition, a recent study found a high prevalence of congenital GI anomalies (adjusted odds ratio 5.1, 95% confidence interval 1.8–14.1), notably pyloric stenosis, in autism, which may be linked to the high rate of GI dysfunction reported by their parents (Wier, Yoshida, Odouli, Grether, & Croen,
2006).
The implication of the GI tract in autistic pathophysiology warrants more detailed investigation of the gut-brain axis (Erickson et al.,
2005). Especially the role of serotonin (5-hydroxytryptamine; 5-HT), as a messenger within this axis (Gershon,
2005), deserves attention. Many different aspects of the 5-HT system in autism have already been studied (Burgess, Sweeten, McMahon, & Fujinami,
2006; Croonenberghs, Verkerk, Scharpe, Deboutte, & Maes,
2005; Janusonis,
2005; Mulder et al.,
2004). A recent report (Mulder et al.,
2004) on platelet (PLT) 5-HT in PDD showed PLT hyperserotonemia in approximately 36% of patients with autism and in 58% of patients with PDD not otherwise specified (NOS). Using mixture-modeling analysis Mulder et al. (
2004) derived an empirical cut-off value that enabled dichotomization of patients with PDD into normo- and hyperserotonemic. Extensive behavioral assessments did, however, not show significant correlates with PLT 5-HT or hyperserotonemic status.
A common (developmental) factor, causing both an autistic brain and deregulated 5-HT release from the GI tract, years after birth, may be involved in the etiology of PDD (Janusonis,
2005). The primary site of the hyperserotonemia in autism is likely to be located in the GI tract. Serotonin is a biogenic amine that derives from the essential amino acid tryptophan (Tryp) by hydroxylation and subsequent decarboxylation. The GI tract contains about 80% of bodily 5-HT, which is unevenly distributed among the enterochromaffin cells (90–95%) and neurons (5–10%) (Houghton, Atkinson, Whitaker, Whorwell, & Rimmer,
2003). The main functions of 5-HT are in smooth muscle contraction, blood pressure regulation, and peripheral and central neurotransmission. Serotonin localized in the basolateral stores of enterochromaffin tissue is released upon neuronal, chemical or mechanical stimulation. Several 5-HT receptors control GI motility, sensation and secretion (Gershon,
2005). Following its release, 5-HT is removed from the interstitial space by 5-HT selective reuptake transporters (Gershon,
2005). However, part of the 5-HT enters the portal blood and systemic circulation where it is either rapidly taken up and accumulated by PLT, or metabolized by the liver, lung and kidneys into its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) (Houghton et al.,
2003). Platelets store and transport the majority (99%) of circulating 5-HT (Ortiz, Artigas, & Gelpi,
1988).
Elevated PLT 5-HT levels observed in subgroups of patients with PDD, may be related to increased GI motility. This notion is supported by higher PLT 5-HT in patients with diarrhea predominant irritable bowel syndrome (d-IBS), as compared with healthy controls (Houghton et al.,
2003), although this was not consistently found (Atkinson, Lockhart, Whorwell, Keevil, & Houghton,
2006). Patients with d-IBS have augmented GI motility, which is likely to cause increased exposure of their circulating PLT to 5-HT (Atkinson et al.,
2006; Gershon,
2005; Houghton et al.,
2003). Increased PLT 5-HT is also observed in patients with carcinoid tumors (Kema et al.,
2001). Carcinoid tumors derive from enterochromaffin cells and are characterized by high 5-HT production with diarrhea as a frequent symptom (Modlin, Kidd, Latich, Zikusoka, & Shapiro,
2005). Consequently, measurement of PLT 5-HT is used as a sensitive marker for the early diagnosis and the subsequent follow-up of patients with carcinoid tumors (Kema et al.,
2001).
The aim of the present study was to investigate whether the subgroup of children with PDD having increased PLT 5-HT levels, is the same as the one exhibiting increased intestinal permeability as established by a SAT.
Discussion
In this study of children with PDD we did not observe a relation between PLT 5-HT and intestinal permeability, as derived from the urinary L/M ratio. The number of children with PDD exhibiting increased PLT 5-HT was lower compared with reports of others. For instance, the recent study of Mulder et al. (
2004) showed 23/81 (28%) of Dutch children with PDD to exhibit increased PLT 5-HT, using the same analytical method and a cut-off value of 5.4 nmol/10
9 PLT. Also our data on intestinal permeability contrast with previous reports (D’Eufemia et al.,
1996; Horvath et al.,
2002) showing that 43–76% of children with autism have increased intestinal permeability, as established by a SAT. A weakness of the current study is its small size and the lack of a local age- and gender matched control group. We have, on the other hand, no indications for deviant reference values for PLT 5-HT or L/M ratios in Curaçao, as compared with The Netherlands. Age and gender do not appear to affect PLT 5-HT (Mulder et al.,
2004), but it must be noted that PLT 5-HT reaches highest levels during childhood and gradually decreases during adulthood (Flachaire et al.,
1990). Dependent on the cut-off values employed, we nevertheless found 4 and 6 patients with increased PLT 5-HT. Neither of these patients had abnormal intestinal permeability or L/M ratios residing in the upper range of normality. However, the positive correlation between PLT 5-HT levels and 24 h urine 5-HIAA, and also the relation between urinary 5-HIAA and urinary 5-HT, suggest that, also in PDD, exposure of PLT to 5-HT determines PLT 5-HT and its consistently found increase in a subgroup. It is possible that increased PLT 5-HT and GI permeability are not consistent features of children with PDD in time. Long term, e.g. monthly, monitoring of a well defined patient and control group may shed more light on this potential source of variance as a cause of the conflicting results found by several investigators. Differences in the activity of the 5-HT transporter based on genetic polymorphisms are unlikely, since these seem to have minor effects, if any, on PLT 5-HT levels (Mulder,
2006).
In conclusion, the finding of a subgroup of children with PDD exhibiting hyperserotonemia was replicated. None of the children exhibited increased intestinal permeability, while PLT 5-HT was unrelated to both intestinal permeability and GI symptoms. Additional studies are needed to elucidate the etiology of increased PLT 5-HT in PDD and to establish its relation with intestinal pathology, if any.